Right time to invest? – Sunrun Inc. (RUN), Atara Biotherapeutics Inc. (ATRA)

You should consider shares of Sunrun Inc. (NASDAQ:RUN) and Atara Biotherapeutics Inc. (NASDAQ:ATRA) if you are looking for a great stocks to invest in. Starting with the RUN shares, which traded at $15.19 at the close of the recent session, dropping -0.52%. On Wednesday, the company’s shares shed -$0.08 from its value which represented in intraday trading. The stock is now 9.99% higher in year-to-date (YTD) trading. RUN’s intraday high was $15.3174 while its lowest price touched $15.05. The stock’s 52-week high price is $21.42, which means the current price is at -29.08%. In terms of trading activity, the daily trading volume fell to 1147271 against 200-day average trading volume of 1,600,725 shares.

What are analyst forecasts for Sunrun Inc. (NASDAQ:RUN)?

At a consensus rating of 4.50, RUN is trending as a streaking Strong Buy, as it has been the case a month ago when 8 analysts called it a Strong Buy. Two months ago, 8 analysts recommended, on average, that RUN stock is a Strong Buy. The Technology company’s shares’ overall bearish trend saw it close higher on Wednesday compared to its opening price of $15.19 on the day.

Forecasts for Sunrun Inc. (NASDAQ:RUN) give the stock a fair value for the growth of 24.05% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $20.00, which means the price per share could rise by nearly $4.81. The price range target is between a low of $17.00 and a high of $25.00. The stock would need to gain by about $39.24 to hit the estimated high or 0.76% from its 12-month low.

The consensus among 9 analysts is that it is a good time for one to Buy in the Sunrun Inc. 7 analysts rate RUN as a Buy, with 0 of 9 analysts rate it as a Sell. 0 have valued the stock as Overweight and 2 have recommended that investors Hold.

Sunrun Inc. (NASDAQ:RUN) Upgrades and Downgrades

In terms of rating changes, KeyBanc Capital Markets on August 20, 2019, Initiated Sunrun Inc. (RUN) at Overweight. They believe the stock could reach $19 in the near term. Analysts at Goldman have assigned a Buy rating for the stock in their research note on June 18, 2019 with an estimated price target of $20. Moreover, Barclays analysts issued a rating of Overweight for the stock on May 16, 2019, giving it a price target of $21 for the next 12 months. On April 25, 2019, the stock earned a Buy rating due to an analyst call from BofA/Merrill, while analysts from BofA/Merrill on September 11, 2018 suggested that the stock is Buy.

Atara Biotherapeutics Inc. (NASDAQ:ATRA) adds -$0.07 on Wednesday

The ATRA stock has risen 1.58% year-to-date and is currently trading at $16.73, which is -60.14% below its 52-week high. The company shares lost -0.42% on the day and have risen nearly 61.18% off a low hit. As of 01/15/20, this stock has fallen -5.91% during the week and closed at $16.80 in the previous session. However, recent Atara Biotherapeutics Inc. stock performance shows that ATRA shares are 8.28% up over the last month, and 31.11% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$1.31, with the trailing 12-month share earnings at -$6.09. The ratio is expected to be down by -5.70% for the current year 2019 and 11.50% for next year. But will the ATRA stock surprise in the current quarter results, where the -$1.31 actual EPS reported on 9/29/2019 surprised by 9.00% or was higher by $0.13 from the estimated -$1.44.

Who owns shares in Atara Biotherapeutics Inc. (ATRA)?

Let’s briefly focus on the share ownership of the Atara Biotherapeutics Inc. (NASDAQ:ATRA) stock, where we find that 113.50% of shares are held by institutions. Baupost Group, Inc,.(The) LLC tops the list of institutional owners as it is holding 8.31 million shares or 15.34% of shares outstanding. Maverick Capital Ltd. and Redmile Group, LLC held 5.1 million and 4.52 million representing 9.43% and 8.35% respectively at the close of the last trading session. As of Sep 29, 2019, Blackrock Inc. accounted for 4.45 million shares at over 62.82 million. This represented 8.22% of shares outstanding. Vanguard Group, Inc. (The) held 3.58 million shares at over 50.57 million representing 6.61% of shares outstanding.

ATRA Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at Atara Biotherapeutics Inc. (ATRA), a total of 3500 shares have been sold by insiders over the last 6 months while 0 shares were added in the same time span. On 2/28/2019, Director by the name Marcus Joel S sold 62590.0 shares worth $2.3 million at the price of $36.07 per share. Filings also show that Ciechanover Issac E sold a total of 24683.0 shares on 2/06/2019 valued at $949600.0. Since the last insider activity, the company’s share price has dropped -56.51%.